Paricalcitol and Multihance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Paricalcitol (paricalcitol) and Multihance (gadobenate dimeglumine). Common drug interactions include nephrogenic systemic fibrosis among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Paricalcitol and Multihance. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Paricalcitol?

Paricalcitol has active ingredients of paricalcitol. eHealthMe is studying from 1,278 Paricalcitol users. Check the latest studies of Paricalcitol.

What is Multihance?

Multihance has active ingredients of gadobenate dimeglumine. eHealthMe is studying from 5,786 Multihance users. Check the latest studies of Multihance.

On Jul, 12, 2026

20 people who take Paricalcitol and Multihance together, and have interactions are studied.

Paricalcitol and Multihance drug interactions.

What are the common drug interactions of Paricalcitol and Multihance, by gender? *:

female:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Joint range of motion decreased (disease of joint movement)
Pain
Oedema peripheral (superficial swelling)
Skin tightness
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Skin hyperpigmentation (disorders affect the colour of your skin)
Deformity (disfigurement)
Skin hypertrophy (skin cells enlarges)
Skin discolouration (change of skin colour)

male:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Skin tightness
Emotional distress
Joint range of motion decreased (disease of joint movement)
Mobility decreased (ability to move is reduced)
Muscular weakness (muscle weakness)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Skin hypertrophy (skin cells enlarges)

What are the common drug interactions of Paricalcitol and Multihance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Arthralgia (joint pain)
Asthenia (weakness)
Deformity (disfigurement)
Erythema (redness of the skin)
Exfoliative rash (scaly red generalized skin rash)
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Gait disturbance
General physical health deterioration (weak health status)
Joint contracture (a permanent shortening of a muscle or joint)
Joint range of motion decreased (disease of joint movement)

50-59:

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Joint range of motion decreased (disease of joint movement)
Deformity (disfigurement)
General physical health deterioration (weak health status)
Skin exfoliation (removal of the oldest dead skin cells)
Skin fibrosis (fibrous tissue formation on skin)
Skin hypertrophy (skin cells enlarges)
Anxiety
Asthenia (weakness)
Emotional distress

60+:

n/a

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 13 people, 65.00%
Nuclear Magnetic Resonance Imaging Abdominal: 9 people, 45.00%
Kidney Transplant Rejection: 4 people, 20.00%
Tenderness (pain or discomfort when an affected area is touched): 1 person, 5.00%
Swelling: 1 person, 5.00%
Renal Cell Carcinoma (a kidney cancer): 1 person, 5.00%
Pain: 1 person, 5.00%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 1 person, 5.00%
Hypotension (abnormally low blood pressure): 1 person, 5.00%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Paricalcitol and Multihance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously